BBNX vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
BBNX exhibits a critically weak Piotroski F-Score of 1/9, indicating severe financial distress, and lacks an Altman Z-Score, preventing a full solvency assessment. Despite strong revenue growth of 63.1% YoY and a robust gross margin of 54.51%, the company is deeply unprofitable with negative operating and net margins, deteriorating earnings, and a negative Forward P/E of -9.72. Insider selling worth $1.32M over the past six months and a bearish technical trend of 0/100 further signal lack of confidence. While analysts maintain a strong_buy consensus with a $31.80 target price, the current fundamentals and cash flow opacity suggest substantial risk.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
BBNX vs LLY: Head-to-Head Comparison
This page compares Beta Bionics, Inc. (BBNX) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.